These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21726253)

  • 1. Every fourth patient with Crohn's disease has anti-TNF dependency.
    Molnár T; Farkas K; Nyári T; Nagy F; Szepes Z; Wittmann T
    Aliment Pharmacol Ther; 2011 Aug; 34(3):400-1. PubMed ID: 21726253
    [No Abstract]   [Full Text] [Related]  

  • 2. [Anti-TNF therapy and Crohn's disease].
    Peyrin-Biroulet L
    Gastroenterol Clin Biol; 2008 May; 32(5 Pt 1):478-81. PubMed ID: 18439777
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-TNF therapy and radiation exposure in Crohn's disease: chicken or egg?
    Magro F; Coelho R; Guimarães LS; Silva M; Peixoto A; Lopes S; Macedo G
    Scand J Gastroenterol; 2016; 51(4):511-2. PubMed ID: 26523855
    [No Abstract]   [Full Text] [Related]  

  • 4. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort.
    Waugh AW; Garg S; Matic K; Gramlich L; Wong C; Sadowski DC; Millan M; Bailey R; Todoruk D; Cherry R; Teshima CW; Dieleman L; Fedorak RN
    Aliment Pharmacol Ther; 2010 Nov; 32(9):1129-34. PubMed ID: 20807218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Commentary: infliximab or adalimumab in Crohn's disease?
    Sprakes MB; Hamlin PJ
    Aliment Pharmacol Ther; 2012 Aug; 36(4):398. PubMed ID: 22803644
    [No Abstract]   [Full Text] [Related]  

  • 6. Fibrotic strictures and anti-TNF-alpha therapy in Crohn's disease.
    Sorrentino D; Terrosu G; Vadalà S; Avellini C
    Digestion; 2007; 75(1):22-4. PubMed ID: 17429204
    [No Abstract]   [Full Text] [Related]  

  • 7. Letter: infliximab and adalimumab in the management of Crohn's disease--are they really comparable?
    Lopez-Sanroman A; Gisbert JP
    Aliment Pharmacol Ther; 2012 Sep; 36(5):498-9. PubMed ID: 22860615
    [No Abstract]   [Full Text] [Related]  

  • 8. Closure of perianal fistula using adalimumab in a Crohn's disease patient naive to antitumor necrosis factor alpha antibodies.
    Malesci A; Angelucci E; Bonifacio C; Sociale O; Omodei P; Repici A; Balzarini L; Danese S
    Inflamm Bowel Dis; 2009 Jun; 15(6):814-5. PubMed ID: 18831523
    [No Abstract]   [Full Text] [Related]  

  • 9. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crohn's disease in common variable immunodeficiency: treatment with antitumor necrosis factor alpha.
    Nos P; Bastida G; Beltran B; Aguas M; Ponce J
    Am J Gastroenterol; 2006 Sep; 101(9):2165-6. PubMed ID: 16968516
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
    Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
    Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esophageal Crohn's disease treated successfully with adalimumab.
    Kwan LY; Conklin JL; Papadakis KA
    Inflamm Bowel Dis; 2007 May; 13(5):639-40. PubMed ID: 17221856
    [No Abstract]   [Full Text] [Related]  

  • 13. "How to manage loss of response to anti-TNF in Crohn's disease? ".
    Reinisch W
    Curr Drug Targets; 2010 Feb; 11(2):152-5. PubMed ID: 20210764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature.
    Jürgens M; Brand S; Filik L; Hübener C; Hasbargen U; Beigel F; Tillack C; Göke B; Ochsenkühn T; Seiderer J
    Inflamm Bowel Dis; 2010 Oct; 16(10):1634-6. PubMed ID: 20027647
    [No Abstract]   [Full Text] [Related]  

  • 15. [Oligosymptomatic alimentary tract perforation in course of Crohn's disease in patient treated with anti-TNF alfa antibodies].
    Jałocha Ł; Wojtuń S; Wojtkowiak M; Błaszak A; Dyrla P; Gil J
    Pol Merkur Lekarski; 2009 May; 26(155):491-2. PubMed ID: 19606707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab for cutaneous metastatic Crohn's disease.
    Cury DB; Moss AC; Elias G; Nakao A
    Inflamm Bowel Dis; 2010 May; 16(5):723-4. PubMed ID: 19728388
    [No Abstract]   [Full Text] [Related]  

  • 17. [Adalimumab therapy in Crohn's disdease].
    Baryshnikov EN; Lazebnik LB; Parfenov AI
    Eksp Klin Gastroenterol; 2009; (5):92-8. PubMed ID: 20205331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: loss of response to anti-TNF treatments in Crohn's disease.
    Ben-Horin S; Chowers Y
    Aliment Pharmacol Ther; 2011 May; 33(9):987-95. PubMed ID: 21366636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
    Absah I; Faubion WA
    Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Crohn's disease at the turn of the century.
    Bickston SJ; Cominelli F
    N Engl J Med; 1998 Aug; 339(6):401-2. PubMed ID: 9691110
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.